Cytori Therapeutics Inc (NASDAQ:CYTX) Short Interest Update

Cytori Therapeutics Inc (NASDAQ:CYTX) was the recipient of a large decline in short interest in June. As of June 30th, there was short interest totalling 152,200 shares, a decline of 33.2% from the May 30th total of 227,800 shares. Based on an average daily volume of 695,900 shares, the short-interest ratio is currently 0.2 days. Currently, 1.2% of the shares of the stock are short sold.

An institutional investor recently raised its position in Cytori Therapeutics stock. Virtu Financial LLC grew its position in shares of Cytori Therapeutics Inc (NASDAQ:CYTX) by 236.8% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 141,209 shares of the biotechnology company’s stock after purchasing an additional 99,279 shares during the period. Virtu Financial LLC owned approximately 0.86% of Cytori Therapeutics worth $36,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 2.62% of the company’s stock.

Shares of CYTX remained flat at $$0.24 during mid-day trading on Thursday. 259,513 shares of the stock were exchanged, compared to its average volume of 620,583. The firm’s 50-day moving average is $0.25. The company has a debt-to-equity ratio of 0.39, a current ratio of 0.46 and a quick ratio of 0.30. Cytori Therapeutics has a 12-month low of $0.21 and a 12-month high of $1.24.

Cytori Therapeutics (NASDAQ:CYTX) last released its quarterly earnings results on Tuesday, May 14th. The biotechnology company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.02. The firm had revenue of $0.70 million during the quarter. Cytori Therapeutics had a negative net margin of 242.60% and a negative return on equity of 272.70%.

A number of research firms have recently commented on CYTX. ValuEngine lowered shares of Zosano Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, May 1st. Maxim Group restated a “hold” rating on shares of Cytori Therapeutics in a research report on Monday, April 1st.

Cytori Therapeutics Company Profile

Cytori Therapeutics, Inc is a late stage cell therapy company, which engages in the development of autologous cell therapies from adipose tissue, using its proprietary technology, to treat a variety of medical conditions. It offers the Cytori Nanomedicine, Cytori Cell Therapy, and other clinical trials.

Featured Article: Depreciation

Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with's FREE daily email newsletter.